Proagiogenic properties of human myeloma cells: Production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis

Blood

Volumn 102, Issue 2, 2003, Pages 638-645

  Giuliani, Nicola ^a   Colla, Simona ^b   Lazzaretti, Mirca ^b   Sala, Roberto ^b   Roti, Giovanni ^b   Mancini, Cristina ^b   Bonomini, Sabrina ^b   Lunghi, Paolo ^b   Hojden, Magda ^b   Genestreti, Giovenzio ^b   Svaldi, Mirija ^b   Coser, Paolo ^b   Fattori, Pier Paolo ^b   Sammarelli, Gabriella ^b   Gazzola, Gian Carlo ^b   Bataille, Regis ^b   Almici, Camillo ^b   Caramatti, Cecilia ^b   Mangoni, Lina ^b   Rizzoli, Vittorio ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 1 RECEPTOR; ANGIOPOIETIN 2; RECEPTOR; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENIC FACTOR; ANGIOPOIETIN RECEPTOR; ANGPT1 PROTEIN, HUMAN; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; MEMBRANE PROTEIN; MEN1 PROTEIN, HUMAN; MESSENGER RNA; MONOCLONAL ANTIBODY; ONCOPROTEIN; RNA; SIGNAL PEPTIDE; TUMOR PROTEIN; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CELL ACTIVITY; CELL FUNCTION; CELL LEVEL; CELL PROLIFERATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SPACE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; BIOSYNTHESIS; DRUG ANTAGONISM; ENDOTHELIUM; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; PLASMA CELL LEUKEMIA; VASCULARIZATION;

ADULT; ANGIOGENESIS INDUCING AGENTS; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANTIBODIES, MONOCLONAL; BONE MARROW CELLS; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, PLASMACYTIC; LYMPHOKINES; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS; RECEPTOR, TIE-2; RNA, MESSENGER; RNA, NEOPLASM; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037480835     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3257     Document Type: Article

References (41)

1. Bataille R, Harousseau J-L. Multiple myeloma. N Engl J Med. 1997;336:1657-1664.
2. Hideshima T, Chauhan D, Podar K, Schlossman R-L, Richardson P, Anderson K-C. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol. 2001;28:607-612.
3. Rajkumar S-V, Mesa R-A, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002;8:2210-2216.
4. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064-3073.
5. Vacca A, Ribatti D, Roccaro A-M, Frigeri A, Dammacco F. Bone marrow angiogenesis in patients with active multiple myeloma. Semin Oncol. 2001;28:543-550.
6. Munshi N-C, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol. 2001;28:565-569.
7. Carmeliet P, Jain R-K. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
8. Yancopoulos G-D, Davis S, Gale N-W, Rudge J-S, Wiegand S-J, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242-248.
9. Holash J, Wiegand S-J, Yancopoulos G-D. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene. 1999;18:5356-5362.
10. Bellamy W-T. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol. 2001;28:551-559.
11. Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95:2630-2636.
12. Gupta D, Treon S-P, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15:1950-1961.
13. Zhang XG, Gaillard JP, Robillard N, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood. 1994;83:3654-3663.
14. Lehr J-E, Pienta K-J. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst. 1998;90:118-123.
15. Rood P-M, Calafat J, von dem Borne A-E, Gerritsen W-R, van der Schoot C-E. Immortalisation of human bone marrow endothelial cells: characterisation of new cell lines. Eur J Clin Invest. 2000;30:618-629.
16. Bussolati B, Dunk C, Grohman M, Kontos C-D, Mason J, Ahmed A. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol. 2001;159:993-1008.
17. Portier M, Zhang X-G, Ursule E, et al. Cytokine gene expression in human multiple myeloma. Br J Haematol. 1993;85:514-520.
18. Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem. 1996;271:24655-24661.
19. Shapiro V-S, Millenauer M-N, Weiss A. Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression. Blood. 2001;98:187-193.
20. Papetti M, Herman I-M. Mechanism of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol. 2001;282:947-970.
21. Suri C, McClain J, Thurston G, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science. 1998;282:468-471.
22. Maisonpierre P-C, Suri C, Jones P-F, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55-60.
23. Hayes A-J, Huang W-Q, Yu J, et al. Expression and function of angiopoietin-1 in breast cancer. Br J Cancer. 2000;83:1154-1160.
24. Tian S, Hayes A-J, Metheny-Barlow L-J, Li L-Y. Stabilization of breast cancer xenograft tumour neovasculature by angiopoietin-1. Br J Cancer. 2002;86:645-651.
25. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands J-R. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest. 1999;103:341-345.
26. Takahama M, Tsutsumi M, Tsujiuchi T, et al. Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. Clin Cancer Res. 1999;5:2506-2510.
27. Mitsutake N, Namba H, Takahara K, et al. Tie2 and angiopoietin-1 expression in human thyroid tumors. Thyroid. 2002;12:95-99.
28. Ahmad S-A, Liu W, Jung Y-D, et al. Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma: a possible mechanism for the initiation of angiogenesis. Cancer. 2001;92:1138-1143.
29. Etoh T, Inoue H, Tanaka S, Barnard G-F, Kitano S, Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. 2001;61:2145-2153.
30. Kukk E, Wartiovaara U, Gunji, et al. Analysis of Tie receptor tyrosine kinase in haemopoietic progenitor and leukaemia cells. Br J Haematol. 1997;98:195-203.
31. Watarai M, Miwa H, Shikami M, et al. Expression of endothelial cell-associated molecules in AML cells. Leukemia. 2002;16:112-119.
32. Muller A, Lange K, Gaiser T, et al. Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia. Leuk Res. 2002;26:163-168.
33. Hangai M, Murata T, Miyawaki N, et al. Angiopoietin-1 upregulation by vascular endothelial growth factor in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42:1617-1625.
34. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol. 1998;153:1459-1466.
35. Uneda S, Matsuno F, Sonoki T, Tniguchi I, Kawano F, Hata H. Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cells. Haematologica. 2003;88:113-115.
36. Christensen R-A, Fujikawa K, Madore R, Oettgen P, Varticovski L. NERF2, a member of the Ets family of transcription factors, is increased in response to hypoxia and angiopoietin-1: a potential mechanism for Tie2 regulation during hypoxia. J Cell Biochem. 2002;85:505-515.
37. Willam C, Koehne P, Jurgensen J-S, et al. Tie2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells. Circ Res. 2000;87:370-377.
38. Bataille R, Klein B, Jourdan M, Rossi J-F, Durie B-G. Spontaneous secretion of tumor necrosis factor-beta by human myeloma cell lines. Cancer. 1989;63:877-880.
39. Takakura N, Huang X-L, Naruse T, et al. Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity. 1998;9:677-686.
40. Lin P, Polverini P, Dewhirst M, Shan S, Rao P-S, Peters K. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest. 1997;100:2072-2078.
41. Huang X-L, Takakura N, Suda T. In vitro effects of angiopoietins and VEGF on hematopoietic and endothelial cells. Biochem Biophys Res Commun. 1999;264:133-138.